Next-gen CAR-T from BMS passes pivotal test in quadruple-class exposed myeloma (Firstwordpharma Press Release) - Sep 9, 2026 - "The results come from the Phase II QUINTESSENTIAL study, which investigated arlo-cel in patients with quadruple-class exposed relapsed and refractory multiple myeloma...Top-line results showed that the trial met its primary endpoint with arlo-cel demonstrating a statistically significant and clinically meaningful overall response rate (ORR) in patients with quadruple-class exposed RRMM who had received four or more prior lines of therapy."
P2 data • Multiple Myeloma
|